Given these roles, targeting the activation of HSCs and inhibiting the TGF-β/mothers against the decapentaplegic homolog 2 and 3 (SMAD 2/3) signaling pathway are promising strategies for treating liver fibrosis. Here, TGFB1 is linked to Hepatic fibrosis.